You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Neurorestorative therapy of stroke with HUCBC in T2DM rats

    SBC: SANERON CCEL THERAPEUTICS, INC.            Topic: NINDS

    DESCRIPTION (provided by applicant): Diabetes mellitus (DM) leads to a 3-4 fold higher risk of experiencing ischemic stroke. In addition, DM stroke patients are more prone to develop more and earlier white matter (WM) high-intensity lesions than non DM stroke patients. Treatment of stroke with tissue plasminogen activator (rtPA) at 2-3 hours after stroke decreases lesion volume in non-DM rats. How ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  2. Novel Highly Regenerative and Scalable Progenitor Cell Exosomes for Treating Stroke

    SBC: BioTime, Inc.            Topic: 100

    ABSTRACT Stroke is a leading cause of disability worldwideGloballythere aremillion stroke survivors each year who have significant neurological deficits including sensory and motor disabilityleading to excessive socioeconomic burdenCell therapy using primary MSCs has been actively explored by us and others as a therapeutic solution to this unmet medical needHoweversince the therapeutic efficacy of ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  3. Novel indication for myeloid progenitor use: Induction of tolerance

    SBC: Cellerant Therapeutics, Inc.            Topic: NIAID

    DESCRIPTION (provided by applicant): State of the art techniques result in 10-year solid organ graft loss of up to 80% in cardiopulmonary organ transplantation, and re-transplantation is often not possible. Establishment of donor-specific immunological tolerance (DSIT), a condition in which a recipient accepts a transplant without immunosuppression, while retaining the ability to fight infections, ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  4. Novel RTL treatment to promote brain repair and cognitive recovery following meth

    SBC: VIROGENOMICS, INC.            Topic: NIDA

    DESCRIPTION (provided by applicant): Methamphetamine (MA) dependence is associated with neuropsychiatric side effects that make the addiction extremely challenging to treat. Patients seeking treatment experience ongoing impairments in cognition, mood, and motivation. Currently, there are no FDA-approved pharmacotherapies for MA dependence. The goal of this proof-of-concept research project is test ...

    STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  5. O-Glycan-dependent Immunotherapy for Cancer

    SBC: GlyTR Therapeutics, Inc.            Topic: 102

    Abstract For decadesthe treatment of cancer has relied on surgical resectionchemotherapy and or radiotherapyRecentlya number of immune based therapies have provided promising new approaches for cancer treatmentThe two most potent immunotherapies are monoclonal antibodymABbased bi specific proteinseg Bispecific T cell engagersBiTEand engineered Chimeric Antigen Receptor T cellsCAR TBoth act by indu ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  6. Online Psychosocial Assessment Instruments Technology Transfer

    SBC: KINNEXXUS, INC.            Topic: NIA

    DESCRIPTION (provided by applicant): As elders age, they need increasing amounts of adaptive assistance and care from their caregivers- people who are often busy or remote. With the baby boomer generation preparing to retire, the sheer number of people who will need support will far outstrip the nation's ability to provide professional caregivers. Furthermore, the nation will not be able to afford ...

    STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  7. Optimization of Protein Therapeutic Formulations

    SBC: SOLUBLE THERAPEUTICS, INC            Topic: NIGMS

    DESCRIPTION (provided by applicant): This proposal involves the development and validation of a novel approach to improve and accelerate the discovery of biopharmaceuticals (i.e. vaccines, monoclonal antibodies and other therapeutic proteins). Biopharmaceuticals are used to treat a variety of infectious and chronic diseases. The proposed research is intended to establish a new paradigm for rapidly ...

    STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  8. Oxygen Production and Delivery on Demand

    SBC: GLOBAL RESEARCH & DEVELOPMENT INC            Topic: DHA17B005

    This proposal is in response to the Defense Health Agency 2017 Phase I SBIR topic 17B-005.The approach is the use of a membrane oxygen pump using newly developed nano-thickness membranes with all the layers less than 1 micron total.Nanometer thickness membranes enable more oxygen output per surface area at temperatures of 300-600 C than current state-of-the -art 600-800 C membranes that are 50-300 ...

    STTR Phase I 2018 Department of DefenseDefense Health Agency
  9. Peripheral FAAH as a target for novel analgesics

    SBC: Anteana Therapeutics Inc            Topic: NIDA

    DESCRIPTION (provided by applicant): Pain management remains a significant unmet medical need. Anandamide is an endogenous marijuana-like ('endocannabinoid') molecule that plays important roles in the regulation of pain. Previous work has shown that endocannabinoid receptors located outside the central nervous system (CNS) exert a powerful regulatory control over pain initiation. Moreove ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  10. Peripheral FAAH inhibitor, URB937, as an opioid-sparing analgesic for chronic pain.

    SBC: ASPIREBIO CORP            Topic: 101

    PROJECT SUMMARY Opioid drugs are powerful analgesicsbut their side effect profile strongly limits their useIndeedtheir addictive properties have led to an epidemic of abuse in the US that accounts forof the global utilization of prescription opioid analgesics in the USwith a market of over $billion per yearPrevious studies have shown that the endocannabinoid neurotransmitteranandamidecontrols noci ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government